Prevention and early detection of Prostate Cancer: a global view Vitaly Smelov, International Agency for Research on Cancer (IARC), World Health Organisation (WHO)
Prevention and early detection of Prostate Cancer: a global view Vitaly Smelov, International Agency for Research on Cancer (IARC), World Health Organisation (WHO)
Presentation at PORTAGE (Paediatric Oncology Roundtable to Transform Access to Global Essentials) Inaugeral Meeting, hosted by Friends of Cancer Patients, Childhood Cancer International and International Society of Paediatric Oncology, 16-18 January 2018, Sharjah, UAE
Women in Nuclear, IAEA Programme of Action for Cancer TherapyAnja Nitzsche-Bell
Introduction to the IAEA Programme of Action for Cancer Therapy (PACT): Maximizing Investments in Radiation Medicine, presented at 23rd WiN Global Annual Conference -
Women in Nuclear Meet Atoms for Peace, Vienna, 2015
The National Comprehensive Cancer Network updated its NCNN Clinical Practice Guidelines in Oncology® to include stereotactic body radiation therapy as a treatment option for prostate cancer. CyberKnife Center of Chicago specializes in stereotactic radiosurgery and stereotactic body radiation therapy using CyberKnife® technology. If you are interested in learning more about CyberKnife Center of Chicago, call 331-221-2050 to speak with a representative.
di Pier Giuseppe Pelicci, MD-PhD, Istituto Europeo di Oncologia IEO, Università degli Studi di Milano.
Slide per l'intervento tenuto in Fondazione Giannino Bassetti in occasione del primo incontro del ciclo "La medicina di precisione", primo progetto dalla convenzione tra Università di Pavia e Fondazione Bassetti.
12 marzo 2018
Presentation at PORTAGE (Paediatric Oncology Roundtable to Transform Access to Global Essentials) Inaugeral Meeting, hosted by Friends of Cancer Patients, Childhood Cancer International and International Society of Paediatric Oncology, 16-18 January 2018, Sharjah, UAE
Women in Nuclear, IAEA Programme of Action for Cancer TherapyAnja Nitzsche-Bell
Introduction to the IAEA Programme of Action for Cancer Therapy (PACT): Maximizing Investments in Radiation Medicine, presented at 23rd WiN Global Annual Conference -
Women in Nuclear Meet Atoms for Peace, Vienna, 2015
The National Comprehensive Cancer Network updated its NCNN Clinical Practice Guidelines in Oncology® to include stereotactic body radiation therapy as a treatment option for prostate cancer. CyberKnife Center of Chicago specializes in stereotactic radiosurgery and stereotactic body radiation therapy using CyberKnife® technology. If you are interested in learning more about CyberKnife Center of Chicago, call 331-221-2050 to speak with a representative.
di Pier Giuseppe Pelicci, MD-PhD, Istituto Europeo di Oncologia IEO, Università degli Studi di Milano.
Slide per l'intervento tenuto in Fondazione Giannino Bassetti in occasione del primo incontro del ciclo "La medicina di precisione", primo progetto dalla convenzione tra Università di Pavia e Fondazione Bassetti.
12 marzo 2018
FINAL-Advocacy-Module 6 Research for advocatesCforCourage
Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body.
Cancer can start almost anywhere in the human body, which is made up of trillions of cells. Normally, human cells grow and multiply (through a process called cell division) to form new cells as the body needs them. When cells grow old or become damaged, they die, and new cells take their place.
Sometimes this orderly process breaks down, and abnormal or damaged cells grow and multiply when they shouldn’t. These cells may form tumors, which are lumps of tissue. Tumors can be cancerous or not cancerous (benign).
Cancerous tumors spread into, or invade, nearby tissues and can travel to distant places in the body to form new tumors (a process called metastasis). Cancerous tumors may also be called malignant tumors. Many cancers form solid tumors, but cancers of the blood, such as leukemias, generally do not.
Benign tumors do not spread into, or invade, nearby tissues. When removed, benign tumors usually don’t grow back, whereas cancerous tumors sometimes do. Benign tumors can sometimes be quite large, however. Some can cause serious symptoms or be life threatening, such as benign tumors in the brain.
Differences between Cancer Cells and Normal Cells
How Does Cancer Develop?
Types of Genes that Cause Cancer
When Cancer Spreads
Tissue Changes that Are Not Cancer
Types of Cancer
Related Resources
Updated: October 11, 2021
If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “What Is Cancer? was originally published by the National Cancer Institute.”
Ariane Weinman presents at ESMO 2021 on how the integration of a specific section on rare cancers into NCCPs can support patients' from diagnosis to treatment
Image-guided liver cancer modeling for computer-aided diagnosis and treatmentAntoine Vacavant
HCC (hepatocellular carcinoma) is the most common primary liver cancer, and the third leading cause of death worldwide. Diagnosis is generally conducted through various medical imaging modalities (ultra-sound, CT, MRI) and, depending on the characterization of HCC (number and size of nodules, early or later staging, etc.), different therapeutic strategies can be delivered to the patient: radiofrequency ablation, liver resection surgery, chemo-embolization, etc. During this talk, I first present a novel ontological approach to represent both HCC detection, staging and treatment into a single information system framework, enabling a complete digital patient follow-up. Since representing numerically liver's geometry is an important concern in such system, I then expose our most recent algorithms devoted to reconstruct the liver volume and inner vessels in 3-D from CT and MRI data. We also see different applications employing the outcomes provided by these tools. (1) The standardized Couinaud liver representation can be calculated thanks to the shape of the vasculature, and permits to locate HCC nodules in a reproducible way. (2) By isolating liver volume, we have proposed to automatically detect HCC tissues within DCE-MRI (dynamic contrast-enhanced MRI) sequences by two approaches: SVM-based classification and adapted U-Net deep learning. (3) We have also studied the numerical simulation of hepatic perfusion by considering finite-element models of the liver and its vessels. This talk finishes by exposing our future prospects in improving our methodologies and combining them for proposing novel computer-aided HCC diagnosis and treatment systems.
Professor Martin Wiseman presentation on The Continuous Update Project: Introduction to the Project at FENS European Nutrition Conference, 20-23 October 2015 Berlin (Germany).
This tool will describe the key components of an abstract, offer practical suggestions for optimising the key messages of your work, provide general advice on abstract preparation and tips for increasing the likelihood of your abstract being accepted for presentation.
This tool will describe the key components of an abstract, offer practical suggestions for optimising the key messages of your work, provide general advice on abstract preparation and tips for increasing the likelihood of your abstract being accepted for presentation
How to write an abstract - Online EAUN Course 2022Marc van Gurp
This educational tool is provided to assist you in the development of your abstract, for submission to the European Association of Urological Nurses (EAUN) annual meeting
This tool is provided to assist you in making a poster for the poster session during the European Association of Urological Nurses (EAUN) Annual Meeting.
This tool is provided to assist you in the development of your scientific poster for oral presentation. It describes the key components of the poster presentation, offer practical suggestions for optimising the key messages of your work, provide general advice on poster preparation and tips for its oral presentation.
How to write an abstract - online EAUN courseMarc van Gurp
This tool will describe the key components of an abstract, offer practical suggestions for optimising the key messages of your work, provide general advice on abstract preparation and tips for increasing the likelihood of your abstract being accepted for presentation.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
EPAD 2017 - Tit Albreht
1. Will the new Joint Action include Prostate Cancer?
CANCON’s vision
Tit Albreht
National Institute of Public Health of Slovenia
2. In the Joint Action (JA) CanCon prostate cancer was a part of the
discussions concerning (potential) screening programmes and as an index
cancer for the description of after-care pathways.
Indirectly, it was included in the discussions on the Comprehensive Cancer
Control Networks (CCCNs) and on Survivorship.
3. Existence of guidelines for certain cancers and for their after-care
Cancer location Number of guidelines Countries with
guidelines
Specific to
after-care*
No. of guidelines
with at least one
scientific reference
to after-care**
Guide for GPs
Breast 24 19 7 17 4
Colorectal
ca.
21 16 6 12 1
Lung 17 11 3 9 1
Melanoma 15 13 1 12 1
Prostate 18 14 4 14 1
Source: European Guide for Quality Improvement in Comprehensive Cancer Control.
www.cancercontrol.eu
4. Recurrence detection [18]
• Physical diagnostic tests [14]
• Diagnostic imaging [8]
• Awareness [13]
Laboratory diagnostic tests [18]
• Risk of recurrence/new cancer [5]
• Organisation of care [7]
• Signs of recurrence [10]
• Pathological diagnostic tests [5]
Long-term effects [11]
• Potential complications [11]
• Treatment of complications [7]
• Psychological support [4]
Recurrence prevention [2]
• Physical activity [2]
• Nutrition [2]
• Weight management [1]
• Alcohol consumption [1]
• Smoking cessation [2]
Existence of guidelines for prostate cancer and for its after-care
6. New screening programmes require step-wise decision-making which
includes the establishment of evidence of effectiveness, benefits that
outweigh the harms and cost-effectiveness.
Once evidence exists to support these criteria, implementation
research in each country is needed to assess the feasibility of fulfilling
the national requirements in practice.
In light of currently available evidence, some prostate cancer
screening policies may be cost-effective but questions remain on the
optimal benefit-harm balance. Forthcoming results of European trials
are expected to inform policy-making on lung cancer screening in
Europe. New trials need to be financed to investigate optimal
strategies for gastric cancer screening.
Key message on screening recommendations and potential
prostate cancer screening (Message 4)
7. Structure of the new Joint Action
WP 1 – Coordination, WP 2 – Dissemination, WP 3 – Evaluation
WP 4 - Roadmap on Implementation and Sustainability of Cancer
Control Actions
WP 5 – Cancer prevention
WP 6 – Genomics in Cancer Control and Care
WP 7 – Cancer Information and Registries
WP 8 – Challenges in Cancer Care
WP 9 – Innovative Therapies in Cancer
WP 10 – Governance of Integrated and Comprehensive Cancer Care
New Joint Action iPAAC (Innovative Partnership
for Action Against Cancer)
8. New Joint Action iPAAC (Innovative Partnership
for Action Against Cancer)
Where would prostate cancer be present?
WP4 – Roadmap on the Implementation and Sustainability for
the Cancer Control Actions
WP5 – Prevention
Screening – innovation and proposal of more effective solutions
of population-based screening programmes and risk
stratification
Early detection strategies and management
9. The new JA iPAAC will further develop early detection and
screening strategies for the cancers that have so far not been
supported by guidelines.
WPs on challenges in cancer care and innovative therapies will
touch upon all cancers.
New Joint Action iPAAC (Innovative Partnership
for Action Against Cancer)